Lapatinib in the treatment of breast cancer

  title={Lapatinib in the treatment of breast cancer},
  author={Gerald M Higa and Jame Abraham},
  journal={Expert Review of Anticancer Therapy},
  pages={1183 - 1192}
  • G. HigaJ. Abraham
  • Published 1 September 2007
  • Medicine, Biology
  • Expert Review of Anticancer Therapy
Within the past 2 years, four separate groups have reported marked improvement in relapse-free survival when trastuzumab was added to adjuvant chemotherapy in patients with HER2-overexpressing breast cancer. These results add further credence to the relevance of this receptor as a tumor target. Despite the significant benefits observed in early and advanced HER2-positive breast cancer, overexpression of the receptor is still associated with a poorer prognosis and an increased risk of disease… 

Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

It is of urgent necessity to elucidate the precise mechanisms of lapatinib resistance and improve the therapeutic use of this agent in clinic, in the hope of providing further scientific support for molecular targeted therapies in HER2+ cancers.

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

The literature on the combination of EGFRis with other molecularly targeted therapeutics or conventional chemotherapeutics is analyzed to understand the current knowledge and to provide potential therapeutic options for TNBC treatment.

Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.

The differences in cardiovascular effects of these two compounds are somewhat unexpected and suggest distinct mechanisms of action, which have clear implications in clinical application and prevention of cardiotoxicity in cardio-oncological approaches.

Breast cancer: beyond the cutting edge

  • G. Higa
  • Medicine
    Expert opinion on pharmacotherapy
  • 2009
The ability to probe at the genomic level increased the authors' understanding of the disease but the improved survival outcomes can be attributed to screening programs, which have altered the pattern of diagnosis and prognosis, and to a number of groundbreaking clinical trials.

Recent Progress and Development of Small Molecule Kinase Inhibitors for the Treatment of Breast Cancer

This review summarized the latest development of kinase inhibitors as breast cancer therapy and recommended drugs to treat breast cancer patients.

Landscape of Combination Therapy Trials in Breast Cancer Brain Metastasis.

This work explores combination trials in breast cancer brain metastasis (BCBM), highlighting deficiencies in trial design and underlining promising combination strategies, and concludes that enhancing drug delivery through blood-brain barrier permeable agents may potentiate the overall therapeutic outcomes.

Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck

The role and applications of the epidermal growth factor receptor (EGFR) inhibitors monoclonal antibodies (moAbs) and tyrosine kinase inhibitors (TKIs) locally advanced as well as metastatic SCCHN are summarized.



Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

Trastuzumab treatment beyond progression appears to be of value, producing responses and clinical benefit, and is well tolerated without significant cardiac toxicity, and the feasibility of this approach warrants examination in prospective trials.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.

We sought to describe patterns of treatment and clinical outcome in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy. One hundred eighty-four consecutive

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

The activity of successive trastuzumab-containing regimens in patients with HER2-overexpressing metastatic breast cancer, as well as the response rate, time to progression and predictive factors for response, are described.

A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer.

The combination of paclitaxel/cetuximab was not considered promising in this population, although further study of this regimen might be warranted, because of prohibitive dermatologic toxicity and disappointing preliminary efficacy.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  • M. CobleighC. Vogel D. Slamon
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer.

  • N. LinL. Carey E. Winer
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Although the study failed to demonstrate the hypothesized level of activity as assessed by RECIST, there is sufficient evidence of clinical effect, albeit preliminary, to suggest that lapatinib can penetrate the CNS.

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study

The data presented clearly strengthen evidence that patients do profit from continued trastuzumab treatment, and the fact that TTP did not decrease significantly from first line to beyond second line treatment is especially noteworthy.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.